

# **MARCH 2014 Montana DUR BOARD PDL MEETING MINUTES**

**Date:** March 26, 2014

**Members Present:** Sather, Brown, Bradley, Burton, Caldwell, Crichton, Putsch, Cobb (phone).

**Others Present:** Dan Petersen, Katie Hawkins, Dave Campana (Medicaid), Kathy Novak (Magellan), Woodmansey and Barnhill (Drug PA/CM unit), and various members of the public and representatives of drug manufacturers.

Lisa Sather called the meeting to order.

**Public Comment Period:** No one offered public comment at this time.  
The February DUR Board meeting minutes were reviewed and approved.

## **Department Update:**

Dave Campana presented the following update to the Board:

The Department continues to review drug pricing methodologies. The Department asked the Board to continue to review classes for appropriate grandfathering. Also, a reminder that therapeutic classes are reviewed for clinical information and cost is not considered. As we receive studies from pharmaceutical manufacturers that are pharmacoeconomic studies these are rejected.

## **PDL Review:**

The Board made the following recommendations to the Department:

### **Group 1- Red class**

<b>CLASS</b>	<b>DRUG NAME</b>	<b>Grandfather</b>	<b>2014 Recommendations</b>
<b>ANTIBIOTICS, INHALED</b>	<b>Bethkis®(tobramycin)-ND; tobramycin-NG</b>	Discontinue grandfathering	Therapeutic alternatives
<b>ANTIFUNGALS, ORAL</b>	<b>ketoconazole, safety</b>		Must have terbinafine and fluconazole; Must have 1 of clotrimazole or nystatin; May add others. Continue PA criteria on ketoconazole.
<b>ANTIHISTAMINES-MIN SEDATING</b>	<b>levocetirizine-NI</b>		Class effect; must have one single ingredient agent
<b>ANTIVIRALS, ORAL</b>	<b>famciclovir-NI</b>		<b>HSV ANTIVIRALS-</b> Class Effect. <b>INFLUENZA ANTIVIRALS-</b> Must have CDC recommended agents which are oseltamivir (Tamiflu®) and zanamivir (Relenza®). May add others.
<b>ANTIVIRALS, TOPICAL</b>	<b>Xerese® (acyclovir/hydrocortisone cream)-NI</b>		Class effect.

<b>BLADDER RELAXANTS</b>	Vesicare (solifenacin), Oxytrol (oxybutynin)-updates		Class effect. Must have 1 long acting agent (either by half-life or dosage form)
<b>BPH AGENTS</b>	Uroxatral® (alfuzosin ER)-updates		<b>ALPHA BLOCKERS</b> - Class effect. <b>ANDROGEN HORMONE INHIB. &amp; COMBOS</b> - Class effect. <b>PDE-5 for BPH</b> -tadalafil will be non-preferred with PA criteria.
<b>BRONCHODILATORS-LONG ACTING, SHORT ACTING</b>	Xopenx® (levalbuterol)-label updates	Discontinue grandfathering on short acting agents.	<b>LONG ACTING AGENTS</b> - Class effect. <b>SHORT ACTING AGENTS</b> - Class effect.
<b>COPD AGENTS</b>	Daliresp®(roflumilast)-NI, updates		Must have ipratropium in some form; May add others. Continue PA Criteria on Daliresp®(roflumilast)
<b>CYTOKINES &amp; CAM ANTAGONISTS</b>	Actemra® (tocilizumab), Cimzia® (certolizumab), Simponi® (golimumab), Stelara® (ustekinumab)-NI	Continue grandfathering for continuity of care	Therapeutic alternatives; Research previous decision to not include anakinra (Kineret®) and report back to the Board.
<b>FLUOROQUINOLONES ORAL</b>	safety update		<b>2nd GENERATION</b> -Class effect. Must have ciprofloxacin. <b>3rd GENERATION</b> -Class effect. (Research local resistance patterns in this category and report back to the Board).
<b>INHALED GLUCOCORTICOID &amp; COMBOS</b>	Aerospan®(flunisolide), Breo-Elipta® (fluticasone furoate & vilanterol) - ND		Class effect.
<b>HEP C AGENTS</b>	Olysio® (simeprevir), Solvaldi® (sofosbuvir)-ND Victrelis® (boceprevir), Incivek® (telaprevir)-NI	Continue grandfathering for continuity of care	Ribavirins- Class effect; Pegylated interferons-Class effect; Must have sofosbuvir (Solvaldi®); May add others. Continue PA criteria on all agents in class.
<b>IMMUNOSUPPRESSANTS</b>	Astagraf XL® (tacrolimus ER)-ND; Hecoria® (tacrolimus)-NI; sirolimus-NG	Continue grandfathering for continuity of care	Must have all chemical entities
<b>INTRANASAL RHINITIS</b>	Astepro® (azelastine), Nasacort® (triamcinolone acetate)-NI		<b>NASAL STEROIDS</b> -Class effect. <b>NASAL ANTIHISTAMINES &amp; OTHERS</b> -Class effect; Must have an ipratropium product.

<b>IMMUNOMODULATOR TOPICAL</b>	<b>NEW Category, Aldara® (Imiquimod), imiquimod, Zyclara® (imiquimod)</b>	<b>No</b>	<b>Class effect</b>
<b>LEUKOTRIENE MODIFIERS</b>	<b>montelukast-NI</b>		<b>Must have montelukast may add zafirlukast</b>
<b>ROSACEA AGENTS, TOPICAL</b>	<b>NEW Category- Finacea® (azelaic acid),Metrocream® (metronidazole), Metrogel® (metronidazole), Metro lotion® (metronidazole), metronidazole cream, metronidazole gel, metronidazole lotion, Miravaso® (brimonidine), Noritate® (metronidazole), Rosadan Kit® (metronidazole)</b>		<b>Must have one metronidazole product: May add others.</b>

### Group 2- Blue class

<b>CLASS</b>	<b>DRUG NAME</b>	<b>GF</b>	<b>2014 Decisions</b>
<b>ACNE AGENTS, TOPICAL</b>			Benzoyl Peroxide Combos-Class effect Benzoyl Peroxide Agents- Class effect Clindamycin Agents-Class Effect Sod. Sulfacet. Agents-Class Effect Azelaic Acid-May add Dapsone topical-May add Top. Retinoids&Combo-Class effect Erythromycin topical-Class Effect <b>*(Kathy will check on Benzoyl Peroxide availability)</b>
<b>ANTIBIOTICS, GI</b>			Must have metronidazole and vancomycin- May add others.
<b>ANTIBIOTICS, TOPICAL</b>			Must have a mupirocin product; may have retapamulin.
<b>ANTIBIOTICS, VAGINAL</b>			Therapeutic alternatives
<b>ANTIPSORIATICS, TOPICAL</b>		<b>Discontinue grandfathering</b>	Class effect; Must have one topical formulation and a scalp formulation.
<b>CEPHALOSPORINS &amp; RELATED AGENTS</b>			2nd Generation Ceph.-Class effect 3rd Generation Ceph. - Class effect
<b>EPINEPHRINE,SELF-INJECT</b>			Class effect
<b>GLUCOCORTICOIDS, ORAL</b>			<u>SHORT ACTING</u> ; cortisone, hydrocortisone - Therapeutic alternatives <u>INTERMEDIATE ACTING</u> ; methylprednisolone, prednisone, and prednisolone- Therapeutic

			alternatives, must include a dosepak. <u>LONG ACTING</u> ; betamethasone, dexamethasone - Therapeutic alternatives. <u>BUDESONIDE</u> - Must have 1 budesonide.
<b>IMMUNOMODULATORS ATOPIC DERMATITIS</b>			Class effect-Must have one.
<b>MACROLIDES &amp; KETOLIDES</b>			Class effect- Must have azithromycin, clarithromycin, erythromycin.
<b>SMOKING CESSATION</b>			Must have a nicotine patch and either nicotine gum or lozenge. Must have Chantix. May add others.
<b>TETRACYCLINES</b>			Must have doxycycline. May add others.
<b>TOPICAL STEROIDS</b>			<u>LOW</u> -Class Effect; must have 1 cream and 1 ointment, may add other forms. <u>MEDIUM</u> -Class Effect; must have 1 cream and 1 ointment, may add other forms. <u>HIGH</u> -Class Effect; must have 1 cream and 1 ointment, may add other forms.

There were no Group 1 agents at this meeting.

The next meeting will be April 23, 2014 at The Great Northern Hotel.

The meeting was adjourned at 4:00.